en · de · es · fr · pt
cjc-1295-notes.peptides6608.com › Info › Cjc-1295 Structure And Mechanism — Complete Guide

Cjc-1295 Structure And Mechanism — Complete Guide

By Editorial Desk · published 2025-12-19 · last reviewed 2026-01-05 · Info

If you have been reading about Albumin conjugation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-01-05. Where a claim depends on a specific study, the study is described rather than over-claimed.

CJC-1295 Structure And Mechanism

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

CJC-1295 Background and Mechanism

The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.

Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.

CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.

Cjc-1295 at a glance

PropertyValueNotes
Physical formLyophilized white powderSupplied as a freeze-dried solid for research use
Molecular weightApproximately 3,647 Da (DAC form)Lower for the variant lacking the albumin-binding moiety
SolubilitySoluble in water and aqueous bufferTypically dissolved in sterile or bacteriostatic water
Typical storage temperature−20 °C or belowDry powder, desiccated and protected from light
Common analytical methodReversed-phase HPLC with mass spectrometryUsed for purity estimation and identity confirmation

Albumin Binding and Duration of Action

Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.

The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.

Related pages on this site

Identity and Naming History

The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.

Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.

Mechanism and Pharmacokinetics

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Background and Molecular Features

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.

Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.

The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.

Background from the literature

==== Aqueous suspensions ==== Aqueous suspensions are suspensions of crystal particles of a compound in water. Estradiol in microcrystalline aqueous suspension for use by intramuscular injection was previously marketed in the 1950s under brand names such as Aquadiol, Diogyn, Progynon Aqueous Suspension, and Progynon Micropellets. It was used at a dose of 0.5 to 1.5 mg 2 or 3 times per week. Newman (1950) found that 0.5 to 2 mg once per week was satisfactory. As such, the preparation presumably had a duration in the range of 2 to 7 days. Microcrystalline aqueous suspensions of estradiol esters, for instance of estradiol benzoate (brand names Agofollin Depot alone and Follivirin in combination with testosterone isobutyrate), have been found to have longer duration of actions than oil solutions of the same esters when administered via intramuscular injection. Whereas the duration of a single intramuscular injection of amorphous estradiol benzoate in oil solution is 6 days, the duration of a single intramuscular injection of microcrystalline estradiol benzoate in aqueous suspension is 16 to 21 days. The duration of crystalline aqueous suspensions is highly dependent on crystal size. Steroids and steroid fatty acid esters are lipophilic and have very low water solubility. When they are suspended in the form of crystals in water, these crystals dissolve slowly, releasing steroid from their surfaces in the process. The larger the particle sizes of the crystals, the slower the dissolution rate.

The adult RDAs are at 1.2 mg/day for women 1.4 mg/day for men. The RDA for pregnancy is 1.4 mg/day, for lactation is 1.5 mg/day. For children ages 1–17 years the RDA increases with age from 0.5 to 1.5 mg/day. The adult UL was set at 40–45 mg/day for women and 50–60 mg/day for men, with the lower values in those ranges for adults over 70 years of age.

Many Irish nationalists sympathised with the Boers as oppressed by British imperialism, much like they viewed themselves. Irish miners already in the Transvaal at the start of the war formed the nucleus of two Irish commandos. The Second Irish Brigade was headed by an Australian of Irish parents, Colonel Arthur Lynch. Groups of Irish volunteers went to fight with the Boers—despite the fact that there were many Irish troops fighting in the British army, including the Royal Dublin Fusiliers. In Britain, the "Pro-Boer" campaign expanded, with writers often idealising the Boer society. The war highlighted the dangers of Britain's policy of non-alignment and deepened her isolation. The 1900 UK general election, also known as the "Khaki election", was called by the Prime Minister, Lord Salisbury, on the back of British victories. There was much enthusiasm for the war at this point, resulting in a victory for the Conservative government. However, support waned as it became apparent the war would not be easy and it dragged on, partially contributing to the Conservatives' spectacular defeat in 1906. There was outrage at scorched earth tactics and conditions in the concentration camps. It became apparent there were serious problems with public health in Britain as up to 40% of recruits in Britain were unfit for conscription, and suffered from medical problems such as rickets and other poverty-related illnesses. This came at a time of increasing concern for the poor in Britain. 22,000 Empire troops were killed.

== Production process == Single-cell proteins develop when microbes ferment waste materials (including wood, straw, cannery and food-processing wastes, residues from alcohol production, hydrocarbons, or human and animal excreta). With 'electric food' processes the inputs are electricity, CO2 and trace minerals and chemicals such as fertiliser. It is also possible to derive SCP from natural gas to use as a resilient food. Similarly SCP can be derived from waste plastic by upcycling. The problem with extracting single-cell proteins from waste products is the dilution and cost. They are found in very low concentrations, usually less than 5%. Engineers have developed ways to increase the concentrations including centrifugation, flotation, precipitation, coagulation, and filtration, or the use of semi-permeable membranes. The single-cell protein must be dehydrated to approximately 10% moisture content and/or acidified to aid in storage and prevent spoilage. The methods to increase the concentrations to adequate levels and the de-watering process require equipment that is expensive and not always suitable for small-scale operations. It is economically prudent to feed the product locally and soon after it is produced.

Sources: en.wikipedia.org

Further detail

== Clinical considerations == Deficiency in human tRNA methylthiotransferase eMtaB has been shown to be responsible for abnormal insulin synthesis and predisposition to type 2 diabetes. Mutations in human GTP cyclase MoaA has been reported to lead to molybdenum cofactor deficiency, a usually fatal disease accompanied by severe neurological symptoms. Mutations in human wybutosine-tRNA modifying enzyme Tyw1 promotes retrovirus infection. Alterations in human tRNA-modifying enzyme Elp3 results in progression into amyotrophic lateral sclerosis (ALS). Mutations in human antiviral RSAD1 has been shown to be associated with congenital heart disease. Mutations in human sulfurtransferase LipA has been implicated in glycine encephalopathy, pyruvate dehydrogenase and lipoic acid synthetase deficiency. Mutations in human methylthiotransferase MiaB are related to impaired cardiac and respiratory functions.

== Definitions == The eluent or eluant is the "carrier" portion of the mobile phase. It moves the analytes through the chromatograph. In liquid chromatography, the eluent is the liquid solvent; in gas chromatography, it is the carrier gas. The eluate contains the analyte material that emerges from the chromatograph. It specifically includes both the analytes and coeluting solutes passing through the column, while the eluent is only the carrier. The elution time of a solute is the time between the start of the separation (the time at which the solute enters the column) and the time at which the solute elutes. The elution volume is the volume of eluent required to cause elution. The elution volume may be enough information to identify solutes under standard conditions for a known mix of solutes in a certain technique. For instance, a mixture of amino acids may be separated by ion-exchange chromatography. Under a particular set of conditions, the amino acids will elute in the same order and at the same elution volume.

=== Philippines === Akbayan condemned the what they view as an attack on Venezuela's sovereignty and on the people's right to self-determination and challenged the United States' justification of self-defense and support of democratic regime change for Venezuelan people. It says that the incident ushured a "new world order" where international disputes are resolved through "brute force" rather than international law. The Makabayan bloc has urged President Bongbong Marcos to issue a clear and unequivocal condemnation on what it calls an "unprovoked" attack on Venezuela. It also reiterates its opposition to the Philippines' Mutual Defense Treaty and Enhanced Defense Cooperation Agreement with the United States.

Fentanyl is a synthetic opioid with a potency 20 to 40 times that of heroin and 100 times that of morphine; its primary legal utilization is in pain management for cancer patients and those recovering from painful surgeries. Illicit use of fentanyl continues to fuel an epidemic of synthetic opioid drug overdose deaths in the US. From 2011 to 2021, synthetic opioid deaths per year increased from 2,600 overdoses to 70,601. Since 2018, fentanyl and its analogues have been responsible for most drug overdose deaths in the US, causing over 71,238 deaths in 2021. Fentanyl is often mixed, cut, or ingested alongside other drugs, including cocaine and heroin, to boost their effects. The fentanyl epidemic has erupted into a highly acrimonious dispute between the US and Mexican governments. While US officials blame the flood of fentanyl crossing the border primarily on Mexican crime groups utilizing Chinese precursors, former Mexican President Andrés Manuel López Obrador insisted that the main source of this synthetic drug was Asia. He argued that the crisis of a lack of family values in the US drives people to use the drug.

==== Type IIs restriction endonuclease assembly ==== Some assembly methods also make use of type IIs restriction endonucleases. These differ from other type II endonucleases as they cut several base pairs away from the recognition site. As a result, the overhang sequence can be modified to contain the desired sequence. This provides Type IIs assembly methods with two advantages – it enables "scar-less" assembly, and allows for one-pot, multi-part assembly. Assembly methods that use type IIs endonucleases include Golden Gate and its associated variants.

Sources: en.wikipedia.org

Background from the literature

Most bat species are polygynous, where males mate with multiple females. Male pipistrelle, noctule, and vampire bats may claim and defend resources that attract females, such as roost sites, and mate with those females. Males unable to claim a site are forced to live on the periphery, where they have less reproductive success. Promiscuity, where both sexes mate with multiple partners, exists in species like the Mexican free-tailed bat and the little brown bat. There appears to be bias towards certain males among females in these bats. In a few species, such as the yellow-winged bat (Lavia frons) and spectral bat, adult males and females form monogamous pairs. Lek mating, where males aggregate and compete for female choice through display, is rare in bats but occurs in the hammerheaded bat. Temperate-living bats typically mate during late summer and autumn, while tropical bats may mate multiple times a year. In hibernating species, males will copulate with females in torpor. Female bats use a variety of strategies to control the timing of pregnancy and birth, to make delivery coincide with maximum food availability and other ecological factors. Females of some species use delayed fertilisation, in which mating occurs in late summer to early autumn, but sperm is stored in the reproductive tract, delaying fertilisation until the following late winter to early spring. Other species exhibit delayed implantation, in which the egg is fertilised after mating but does not experience all its cell divisions until external conditions become favourable.

A long amino-terminal non-collagenous domain (NC-1) of 120 amino acids which can be divided in three parts: a short cytoplasmic region, a transmembrane region and a short extracellular region. A 420-amino-acid-long extracellular region organized in three collagenous (COL1, COL2 and COL3) domains which are interrupted by short non-collagenous domains (NC2, NC3 and NC4), as shown in the schematic.

For a given total heat output, reducing waste volume increases heat density; the space required in a repository also depends on the host rock and its temperature limits. Radioactivity is not the same as the dose potentially received from a waste repository. A 2023 DOE assessment noted that waste radiotoxicity is strongly linked to actinide content, while mobile, long-lived fission and activation products can be important contributors to repository dose. Under typical repository conditions, actinides move more slowly than these products. In principle, breeder fuel cycles can recycle and consume all actinides, leaving only fission products. The table illustrates the gap between medium-lived and long-lived fission products. A 2015 measurement put the half-life of samarium-151, one of the medium-lived fission products, at 94.6±0.6 years. As a result of this physical oddity, after several hundred years in storage, the activity of the radioactive waste from an FBR would quickly drop to the low level of the long-lived fission products. However, to obtain this benefit requires the highly efficient separation of transuranics from spent fuel. If the fuel reprocessing methods used leave a large fraction of the transuranics in the final waste stream, this advantage would be greatly reduced. The FBR's fast neutrons can fission actinide nuclei with even numbers of both protons and neutrons. Such nuclei usually lack the low-speed "thermal neutron" resonances of fissile fuels used in LWRs. The thorium fuel cycle inherently produces lower levels of heavy actinides.

== Collaboration == Tecemotide was developed – until Clinical trial phase II – by the Canadian biotech company Biomira Inc., which changed its company name to Oncothyreon Inc. in 2007. Oncothyreon is now located in Seattle, Washington, and it changed its name to SGEN after a merger and acquisition in March 2018. In 2001, Merck KGaA, of Darmstadt, Germany, entered into a collaboration and supply agreement with Biomira. In 2007, Merck KGaA acquired the exclusive worldwide marketing rights from Biomira, and Merck KGaA has since then been entirely responsible for the further clinical development of tecemotide. In 2008, Merck KGaA acquired the manufacturing rights for tecemotide from Oncothyreon. In 2011, Ono Pharmaceutical Company, of Japan, acquired a co-development and co-marketing license for tecemotide in Japan; Ono paid Merck KGaA 5 million euros.

Sources: en.wikipedia.org

Frequently asked questions

How does CJC-1295 differ from modified GRF(1-29)?

The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.

Is CJC-1295 an approved medicine?

It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.

What is known about its half-life?

Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.

What distinguishes CJC-1295 from natural GHRH?

The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.

Network